Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice
- PMID: 11571503
- DOI: 10.1038/sj.bmt.1703140
Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice
Abstract
We investigated the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on peripheral blood progenitor cell (PBPC) mobilization and the combined effect of PEG-rHuMGDF plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) in C57BL/6 mice. Treatment of mice with PEG-rHuMGDF increased the numbers of day 8 and day 12 spleen colony-forming units (CFU-S), and pre-CFU-S in the PB. Ten days administration of PEG-rHuMGDF could mobilize higher numbers of days 8 and day 12 CFU-S than 5 days administration. An optimal dose of PEG-rHuMGDF mobilized a higher number of committed progenitor cells (day 8 CFU-S) and a lower number of immature progenitor cells (pre-CFU-S) into PB than rhG-CSF. The combined administration of optimal or suboptimal doses of PEG-rHuMGDF and rhG-CSF induced synergistic effects on mobilization of CFU-S and pre-CFU-S into PB compared to either factor alone. Four months after sex-mismatched PBPC transplantation, long-term donor-derived engraftment was observed in all recipients that had been transplanted with PBPCs mobilized by rhG-CSF and/or PEG-rHuMGDF, as determined by Y-chromosome polymerase chain reaction (PCR) analysis. Our data suggest that cytokine-induced pathways for PBPC mobilization may be different between PEG-rHuMGDF and rhG-CSF and indicate that PEG-rHuMGDF alone or the combination with rhG-CSF may be useful in effective PBPC mobilization.
Similar articles
-
Effect of cytokine treatment (granulocyte colony-stimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice.Exp Hematol. 1996 Jun;24(7):816-22. Exp Hematol. 1996. PMID: 8647232
-
A synergistic increase in transplantable peripheral blood stem cells in mice by co-administration of recombinant human interleukin 6 and recombinant human granulocyte colony-stimulating factor.Transplantation. 1995 Jun 15;59(11):1596-600. Transplantation. 1995. PMID: 7539959
-
Hematopoietic progenitor cell mobilization into the peripheral blood of mice using a combination of recombinant rat stem cell factor (rrSCF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF).Exp Hematol. 1995 Oct;23(11):1180-6. Exp Hematol. 1995. PMID: 7556528
-
Thrombopoietin: biology and clinical potentials.Int J Hematol. 1999 Dec;70(4):216-25. Int J Hematol. 1999. PMID: 10643146 Review.
-
[Collection of hematopoietic progenitor cells from healthy donors].Acta Med Croatica. 2009 Jun;63(3):237-44. Acta Med Croatica. 2009. PMID: 19827352 Review. Croatian.
Cited by
-
[Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].Zhonghua Xue Ye Xue Za Zhi. 2021 Jan 14;42(1):82-86. doi: 10.3760/cma.j.issn.0253-2727.2021.01.017. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33677876 Free PMC article. Chinese. No abstract available.
-
The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span.Geroscience. 2018 Jun;40(3):221-242. doi: 10.1007/s11357-018-0027-x. Epub 2018 Jun 14. Geroscience. 2018. PMID: 29948868 Free PMC article. Review.
-
Comparison of the efficacy of hematopoietic stem cell mobilization regimens: a systematic review and network meta-analysis of preclinical studies.Stem Cell Res Ther. 2021 May 29;12(1):310. doi: 10.1186/s13287-021-02379-6. Stem Cell Res Ther. 2021. PMID: 34051862 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources